Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ$44.56-0.47 (-1.04%)
Market Cap
$2.21B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
191 of 925
Rank in Industry
115 of 528
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
MIRM Insider Trading Activity
MIRM Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $370,967 | 10 | 37 |
Sells | $5,860,158 | 17 | 63 |
Related Transactions
| Heron Patrick J | director | 8 | $269,767 | 0 | $0 | $269,767 |
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | 2 | $101,200 | 0 | $0 | $101,200 |
| Ramasastry Saira | director | 0 | $0 | 1 | $128,400 | $-128,400 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER | 0 | $0 | 5 | $257,150 | $-257,150 |
| Quan Joanne | CHIEF MEDICAL OFFICER | 0 | $0 | 1 | $319,598 | $-319,598 |
| Vig Pamela | CHIEF SCIENTIFIC OFFICER | 0 | $0 | 1 | $1.04M | $-1.04M |
| Radovich Peter | PRESIDENT AND COO | 0 | $0 | 5 | $1.15M | $-1.15M |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER | 0 | $0 | 4 | $2.96M | $-2.96M |
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, …
Insider Activity of Mirum Pharmaceuticals, Inc.
Over the last 12 months, insiders at Mirum Pharmaceuticals, Inc. have bought $370,967 and sold $5.86M worth of Mirum Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Mirum Pharmaceuticals, Inc. have bought $1.37M and sold $5.03M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Heron Patrick J (director) — $269,767. BJERKHOLT ERIC (CHIEF FINANCIAL OFFICER) — $101,200.
The last purchase of 963 shares for transaction amount of $42,155 was made by Heron Patrick J (director) on 2025‑03‑11.
List of Insider Buy and Sell Transactions, Mirum Pharmaceuticals, Inc.
| 2025-03-11 | Heron Patrick J | director | 963 0.002% | $43.77 | $42,155 | +2.87% | ||
| 2025-03-10 | Heron Patrick J | director | 1,335 0.0027% | $42.97 | $57,363 | +4.80% | ||
| 2025-03-07 | Heron Patrick J | director | 580 0.0012% | $43.21 | $25,064 | +1.34% | ||
| 2025-03-06 | Heron Patrick J | director | 1,335 0.0027% | $43.89 | $58,597 | +0.62% | ||
| 2025-03-05 | Heron Patrick J | director | 267 0.0005% | $44.55 | $11,894 | -2.56% | ||
| 2025-03-04 | Sale | Radovich Peter | PRESIDENT AND COO | 14,850 0.0305% | $45.58 | $676,928 | -3.27% | |
| 2025-03-04 | Heron Patrick J | director | 1,335 0.0027% | $45.57 | $60,830 | -3.27% | ||
| 2025-03-03 | Sale | Peetz Christopher | CHIEF EXECUTIVE OFFICER | 40,000 0.0836% | $46.91 | $1.88M | -4.28% | |
| 2025-02-03 | Sale | Peetz Christopher | CHIEF EXECUTIVE OFFICER | 9,102 0.0187% | $48.22 | $438,921 | +3.28% | |
| 2025-02-03 | Sale | Radovich Peter | PRESIDENT AND COO | 2,627 0.0054% | $48.22 | $126,681 | +3.28% | |
| 2025-02-03 | Sale | Howe Jolanda | SVP, GLOBAL CONTROLLER | 1,064 0.0022% | $48.22 | $51,309 | +3.28% | |
| 2025-01-24 | Sale | Peetz Christopher | CHIEF EXECUTIVE OFFICER | 6,837 0.0143% | $47.92 | $327,658 | +3.94% | |
| 2025-01-24 | Sale | Radovich Peter | PRESIDENT AND COO | 3,177 0.0066% | $47.92 | $152,256 | +3.94% | |
| 2025-01-24 | Sale | Howe Jolanda | SVP, GLOBAL CONTROLLER | 902 0.0019% | $47.92 | $43,228 | +3.94% | |
| 2025-01-17 | Sale | Quan Joanne | CHIEF MEDICAL OFFICER | 6,969 0.0143% | $45.86 | $319,598 | +3.57% | |
| 2025-01-07 | Sale | Peetz Christopher | CHIEF EXECUTIVE OFFICER | 7,489 0.0159% | $42.82 | $320,644 | +15.26% | |
| 2025-01-07 | Sale | Radovich Peter | PRESIDENT AND COO | 1,998 0.0043% | $42.82 | $85,545 | +15.26% | |
| 2025-01-07 | Sale | Howe Jolanda | SVP, GLOBAL CONTROLLER | 750 0.0016% | $42.82 | $32,111 | +15.26% | |
| 2024-11-14 | Sale | Howe Jolanda | SVP, GLOBAL CONTROLLER | 2,500 0.0053% | $47.10 | $117,752 | -2.53% | |
| 2024-09-18 | Heron Patrick J | director | 115 0.0002% | $37.40 | $4,301 | +13.48% |
Total: 105
*Gray background shows transactions not older than one year
Insider Historical Profitability
26.78%
| Heron Patrick J | director | 168123 0.343% | $7.57M | 13 | 0 | +0.01% |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER | 115920 0.2365% | $5.22M | 4 | 9 | +41.16% |
| Vig Pamela | CHIEF SCIENTIFIC OFFICER | 27406 0.0559% | $1.23M | 1 | 6 | +53.04% |
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | 14000 0.0286% | $630,420.00 | 3 | 0 | <0.0001% |
| BARRIS PETER J | 10 percent owner | 4186243 8.5409% | $188.51M | 1 | 0 | +5.09% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$66,492,695 | 135 | 27.65% | $2.08B | |
$1,376,668 | 53 | 18.46% | $2.29B | |
Mirum Pharmaceuticals, Inc. (MIRM) | $224,267,561 | 40 | 26.78% | $2.21B |
$62,927,079 | 29 | 14.02% | $2.14B | |
$150,253,463 | 26 | -52.83% | $2.25B |
MIRM Institutional Investors: Active Positions
| Increased Positions | 115 | +65.34% | 4M | +6.79% |
| Decreased Positions | 74 | -42.05% | 3M | -6.47% |
| New Positions | 41 | New | 1M | New |
| Sold Out Positions | 14 | Sold Out | 637,134 | Sold Out |
| Total Postitions | 217 | +23.3% | 53M | +0.31% |
MIRM Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Frazier Life Sciences Management, L.P. | $312,554.00 | 13.41% | 6.57M | 0 | 0% | 2024-12-31 |
| Janus Henderson Group Plc | $217,949.00 | 9.35% | 4.58M | +101,358 | +2.26% | 2024-12-31 |
| Blackrock, Inc. | $163,385.00 | 7.01% | 3.43M | +66,471 | +1.97% | 2024-12-31 |
| Bvf Inc/Il | $133,030.00 | 5.71% | 2.8M | -279,394 | -9.08% | 2024-12-31 |
| Eventide Asset Management, Llc | $124,012.00 | 5.32% | 2.61M | -838,425 | -24.34% | 2024-12-31 |
| Vanguard Group Inc | $115,345.00 | 4.95% | 2.42M | -71,378 | -2.86% | 2024-12-31 |
| Citadel Advisors Llc | $71,887.00 | 3.08% | 1.51M | +119,774 | +8.61% | 2024-12-31 |
| Novo Holdings A/S | $71,355.00 | 3.06% | 1.5M | 0 | 0% | 2024-12-31 |
| Rock Springs Capital Management Lp | $70,002.00 | 3% | 1.47M | -108,924 | -6.89% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $67,679.00 | 2.9% | 1.42M | +138,623 | +10.79% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.